Heart failure-induced cachexia

Arquivos Brasileiros de Cardiologia

Volumn 100, Issue 5, 2013, Pages 476-482

  Okoshi, Marina Politi ^a   Romeiro, Fernando G ^a   Paiva, Sergio A R ^a   Okoshi, Katashi ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Anorexia; Cachexia; Heart failure; Prognosis

Indexed keywords

ALDOSTERONE; ALPHA TOCOPHEROL; ANGIOTENSIN II; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CATECHOLAMINE; DIGITALIS; FOLLISTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MEDROXYPROGESTERONE; MEGESTROL; MYOSTATIN; NEUROHORMONE; PENTOXIFYLLINE; RETINOL; SODIUM; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP;

ANOREXIA; BIOSYNTHESIS; CACHEXIA; CALCIUM TRANSPORT; FOOD INTAKE; HEART FAILURE; HUMAN; IMMUNOLOGY; MALABSORPTION; NAUSEA AND VOMITING; NONHUMAN; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; WATER DEPRIVATION; WEIGHT REDUCTION;

CACHEXIA; HEART FAILURE; HUMANS;

EID: 84878436232     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130060     Document Type: Review

References (80)

1. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96(2):526-34.
2. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20(9):683-93.
3. Veloso LG, de Oliveira MT Jr, Munhoz RT, Morgado PC, Ramires JA, Barretto AC. [Nutritional repercussion in advanced heart failure and its value in prognostic assessment]. Arq Bras Cardiol. 2005;84(6):480-5.
4. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165(1):55-61.
5. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43(8):1439-44.
6. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol. 2011;146(3):359-63.
7. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor of mortality in chronic heart failure. Lancet. 1997;349(9058):1050-3.
8. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077-83.
9. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793-9.
10. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol. 2010;144(3):347-9.
11. Anker SD, Laviano A, Filippatos G, John M, Paccagnella A, Ponikowski P, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr. 2009;28(4):455-60.
12. Velloso LG, Csengeri LF, Alonso RR, Ciscato CM, Barreto AC, Bellotti G, et al. [Malnutrition in dilated cardiomyopathy: correlation with echocardiographic indices of left ventricular function]. Arq Bras Cardiol. 1992;58(3):189-92.
13. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115(3):836-47.
14. Celik T, Yaman H. Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol. 2010;144(2):319-20.
15. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail. 2009;11(6):567-72.
16. Von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227-52.
17. Romeiro FG, Okoshi K, Zornoff LA, Okoshi MP. Gastrointestinal changes associated to heart failure. Arq Bras Cardiol. 2012;98(3):273-7.
18. Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012;157(1):80-5.
19. Sandek A, Anker SD, von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab. 2009;10(1):22-8.
20. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561-9.
21. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008;125(2):240-5.
22. Raja K, Kochhar R, Sethy PK, Dutta U, Bali HK, Varma JS. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc. 2004;60(6):887-93.
23. Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail. 2004;6(4):403-7.
24. Wrigley BJ, Lip GYH, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011;13(11):1161-71.
25. von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD. Inflammatory biomarkers in heart faiulre revisited: much more than innocent bystanders. Heart Fail Clin. 2009;5(4):549-60.
26. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-41.
27. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201-6.
28. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9.
29. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97(14):1382-91.
30. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104(7):826-31.
31. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev. 2006;11(1):83-92.
32. Boxall BW, Clark AL. Beta-blockers and weight change in patients with chronic heart failure. J Card Fail. 2012;18(3):233-7.
33. rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22(8):1257-66.
34. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004;91(2-3):87-91.
35. Werner C, Werdan K, Ponicke K, Brodde OE. Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. Basic Res Cardiol. 2001;96(3):290-8.
36. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26(22):2368-74.
37. Schulze PC. Protein catabolism and impairment of skeletal muscle insulin signalling in heart failure. Clin Sci (Lond). 2010;119(11):465-6.
38. Toth MJ, LeWinter MM, Ades PA, Matthews DE. Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation. Clin Sci (Lond). 2010;119(11):467-76.
39. Lima AR, Martinez PF, Okoshi K, Guizoni DM, Zornoff LA, Campos DH, et al. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure. Int J Exp Pathol. 2010;91(1):54-62.
40. Damatto RL, Martinez PF, Lima AR, Cezar MD, Campos DH, Oliveira Junior SA, et al. Heart failure-induced skeletal myopathy in spontaneously hypertensive rats. Int J Cardiol. 2012 Mar 29. [Epub ahead of print].
41. Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39(5):1321-6.
42. Okoshi MP, Okoshi K, Pai VD, Pai-Silva MD, Matsubara LS, Cicogna AC. Mechanical, biochemical, and morphological changes in the heart from chronic food restricted rats. Can J Physiol Pharmacol. 2001;79(9):754-60.
43. Okoshi K, Matsubara LS, Okoshi MP, Cicogna AC, Fioretto JR, Padovani CR, et al. Food restriction-induced myocardial dysfunction demonstrated by the combination of in vivo and in vitro studies. Nutr Res. 2002;22(11):1353-64.
44. Cicogna AC, Padovani CR, Okoshi K, Matsubara LS, Aragon FF, Okoshi MP. The influence of temporal food restriction on the performance of isolated cardiac muscle. Nutr Res. 2001;21(4):639-48.
45. Okoshi MP, Okoshi K, Matsubara LS, Dal Pai-Silva M, Gut AL, Padovani CR, et al. Myocardial remodeling and dysfunction are induced by chronic food restriction in spontaneously hypertensive rats. Nutr Res. 2006;26(11):567-72.
46. Okoshi K, Fioretto JR, Okoshi MP, Cicogna AC, Aragon FF, Matsubara LS, et al. Food restriction induces in vivo ventricular dysfunction in spontaneously hypertensive rats without impairment of in vitro myocardial contractility. Braz J Med Biol Res. 2004;37(4):607-13.
47. Cicogna AC, Padovani CR, Georgette JC, Aragon FF, Okoshi MP. Efeito da restrição protéico-calórica sobre a função mecânica dos músculos cardíacos hipertrofiados. Arq Bras Cardiol. 1999;72(4):431-5.
48. Cicogna AC, Padovani CR, Okoshi K, Aragon FF, Okoshi MP. Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle. Am J Med Sci. 2000;320(4):244-8.
49. Sugizaki MM, Carvalho RF, Aragon FF, Padovani CR, Okoshi K, Okoshi MP, et al. Myocardial dysfunction induced by food restriction is related to morphological damage in normotensive middle-aged rats. J Biomed Sci. 2005;12(4):641-9.
50. Gut AL, Okoshi MP, Padovani CR, Aragon FF, Cicogna AC. Myocardial dysfunction induced by food restriction is related to calcium cycling and beta-adrenergic system changes. Nutr Res. 2003;23(7):911-9.
51. Gut AL, Sugizaki MM, Okoshi MP, Carvalho RF, Pai-Silva MD, Aragon FF, et al. Food restriction impairs myocardial inotropic response to calcium and beta-adrenergic stimulation in spontaneously hypertensive rats. Nutr Res. 2008;28(10):722-7.
52. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85(4):1364-73.
53. Poehlman ET. Special considerations in design of trials with elderly subjects: unexplained weight loss, body composition and energy expenditure. J Nutr. 1999;129:260S-263S.
54. Martinez PF, Okoshi K, Zornoff LA, Carvalho RF, Oliveira Junior SA, Lima AR, et al. Chronic heart failure-induced skeletal muscle atrophy, necrosis, and changes in myogenic regulatory factors. Med Sci Monit. 2010;16(12):BR374-83.
55. Dalla Libera L, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol. 2001;33(10):1871-8.
56. Carvalho RF, Cicogna AC, Campos GE, Assis JM, Padovani CR, Okoshi MP, et al. Myosin heavy chain expression and atrophy in rat skeletal muscle during transition from cardiac hypertrophy to heart failure. Int J Exp Pathol. 2003;84(4):201-6.
57. Carvalho RF, Dariolli R, Justulin Junior LA, Sugizaki MM, Politi Okoshi M, Cicogna AC, et al. Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. Int J Exp Pathol. 2006;87(6):437-43.
58. Bueno CR Jr, Ferreira JC, Pereira MG, Bacurau AV, Brum PC. Aerobic exercise training improves skeletal muscle function and Ca2+ handling-related protein expression in sympathetic hyperactivity-induced heart failure. J Appl Physiol. 2010;109(3):702-9.
59. Esposito F, Mathieu-Costello O, Shabetai R, Wagner PD, Richardson RS. Limited maximal exercise capacity in patients with chronic heart failure: partitioning the contributors. J Am Coll Cardiol. 2010;55(18):1945-54.
60. Rosca MG, Okere IA, Sharma N, Stanley WC, Recchia FA, Hoppel CL. Altered expression of the adenine nucleotide translocase isoforms and decreased ATP synthase activity in skeletal muscle mitochondria in heart failure. J Mol Cell Cardiol. 2009;46(6):927-35.
61. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation. 2000;102(15):1847-53.
62. Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol. 2006;109(2):179-87.
63. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818-27.
64. Ghali JK. Anemia and heart failure. Curr Opin Cardiol. 2009;24(2):172-8.
65. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485-9.
66. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-7.
67. Jankowska EA, Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin. 2010;6(3):295-304.
68. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1(1):35-42.
69. Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuous nasoenteric feeding. Am J Clin Nutr. 1989;50(3):539-44.
70. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol. 2003;42(7):1218-23.
71. Fildes JE, Shaw SM, Yonan N, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol. 2009;53(12):1013-20.
72. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109(13):1594-602.
73. Shaw SM, Shah MK, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009;11(2):113-8.
74. El Desoky ES. Drug therapy of heart failure: an immunologic view. Am J Ther. 2011;18(5):416-25.
75. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54(10):919-27.
76. Downing J, Balady GJ. The role of exercise training in heart failure. J Am Coll Cardiol. 2011;58(6):561-9.
77. Kinugawa T, Kato M, Ogino K, Osaki S, Tomikura Y, Igawa O, et al. Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. Int J Cardiol. 2003;87(1):83-90.
78. Niebauer J, Clark AL, Webb-Peploe KM, Coats AJ. Exercise training in chronic heart failure: effects of pro-inflammatory markers. Eur J Heart Fail. 2005;7(2):189-93.
79. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003;42(5):861-8.
80. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002;39(4):653-63.